以控制白细胞迁移通路为靶点的生物制剂和小分子物质治疗炎症性肠病:从基础到临床  

Biologics and small molecules targeting leukocyte trafficking in inflammatory bowel disease:from basic pathogenesis to clinical trials

作　　者：朱明明[1] 冉志华[1] Zhu Mingming;Ran Zhihua(Division of Gastroenterology and Hepatology,Shanghai Inflammatory Bowel Disease Research Center,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai Institute of Digestive Disease,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院消化内科,上海市消化疾病研究所,上海市炎症性肠病研究中心,200127

出　　处：《中华炎性肠病杂志（中英文）》2020年第1期20-24,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：国家自然科学基金(81670497)。

摘　　要：炎症性肠病(IBD)发病机制复杂,白细胞向肠道的迁移增加是IBD异常免疫应答的关键。本文将对控制白细胞迁移通路为靶点的生物制剂和小分子物质进行论述,总结这类药物的基础和临床研究相关进展。The pathogenesis of inflammatory bowel disease(IBD)is complicated,and leukocyte trafficking to the gastrointestinal tract is the key to the abnormal immune response of IBD.We review the biological agents and small molecules that target the leukocyte trafficking pathway,and summarize the current basic and clinical research progress of using this approach to treat IBD patients.

关 键 词：炎症性肠病 白细胞迁移 生物制剂 小分子药物 

分 类 号：R57[医药卫生—消化系统]